Business
– Some of the company’s Israeli shareholders having been cashing in on the share’s record price. – David Reis CEO Stratasys – The share...
Hi, what are you looking for?
– Some of the company’s Israeli shareholders having been cashing in on the share’s record price. – David Reis CEO Stratasys – The share...
– In its 2014 guidance Teva provides a pessimistic scenario with generic Copaxone competition, and an optimistic one with Copaxone exclusivity. – CEO Eyal...
– Teva sees $3 billion in potential sales by 2020 from 50 new therapeutic entities. – Dr. Michael Hayden – 50 new products with...
– The companies have agreed to settle pending patent litigation involving Copaxone in the UK, Netherlands and France. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA;...
– “I’m proud of my previous job at Teva, which was built so impressively by Eli Hurvitz. Teva has wonderful and dedicated people who...
– The network security company’s main patents are about to expire. – Check Point’s founder, chairman and CEO Gil Shwed – / By Shmulik Shelach...
– The court dismissed a motion to put a lower court ruling on hold while it decides Teva’s appeal against earlier invalidation of Copaxone’s...
– Perrigo is acquiring Ireland’s Elan, a beneficiary of royalties from rival multiple sclerosis treatment, Tysabri. – – A safety warning by the US...
– Assuming that Check Point pays a tax rate of 5-6%, its tax liability will be $82-102 million (NIS 300-360 million). – Check Point...
– In July, the US Court of Appeals upheld a lower court decision invalidating four patents on the blockbuster MS treatment. – – Reuters...